Thermo Fisher Scientific Durvalumab Monoclonal Antibody (15D6)

Applications

Tested Dilution

Publications

ELISA (ELISA)

0.01-0.1 µg/mL

-

Blocking Assay (BLOCK)

5-30 µg/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG2a, kappa

Class

Monoclonal

Type

Antibody

Clone

15D6

Immunogen

Durvalumab

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

Protein A

Storage buffer

PBS, pH 7.4

Contains

0.02% sodium azide

Storage conditions

-20°C or -80°C if preferred

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.

Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1kappa monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).Anti-Durvalumab Antibody (15D6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Durvalumab.

Target Information

Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1 kappa monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.